Valuation
- Market cap
- 51,989,000
- Revenue TTM
- $800,000
- Net income TTM
- $-45,350,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -5,668.75%
- Debt to equity
- 0.00
Trading
- Volume
- 7,800
- Avg volume
- 13,212
- Day's range
- $4.56 – $4.68
- Shares out
- 11,351,000
- Stochastic %K
- 9%
- Beta
- 0.74
- Analysts
- Sell
- Price target
- $18.00
Company profile
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Onco...
Show more
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 345 6265
- Website
- https://www.inmagenebio.com
- Address
- 12526 High Bluff Drive, Suite 345, San Diego, United States
Latest news
No headlines yet.
